Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease

Journal of Psychiatric Research

Volumn 53, Issue 1, 2014, Pages 166-172

  Faria, Mayara Chaves ^a   Gonçalves, Gisele Santos ^a   Rocha, Natália Pessoa ^a   Moraes, Edgar Nunes ^a   Bicalho, Maria Aparecida ^a   Gualberto Cintra, Marco Túlio ^a   Jardim de Paula, Jonas ^a   José Ravic de Miranda, Luís Felipe ^a   Clayton de Souza Ferreira, Alessandro ^b   Teixeira, AntÔnio Lúcio ^a   Gomes, Karina Braga ^a   Carvalho, Maria das Graças ^a   Sousa, Lirlândia P ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Instituto Hermes Pardini   (Brazil)

Author keywords

Biomarkers; Brain derived neurotrophic factor; Inflammation; Neurodegeneration; Neurotrophic factors; Neurotrophins; STNFR1

Indexed keywords

ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLINESTERASE INHIBITOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEURONAL GROWTH FACTOR; NEUROTROPHIC FACTOR; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR-ALPHA SOLUBLE RECEPTOR 1; TUMOR NECROSIS FACTOR-ALPHA SOLUBLE RECEPTOR 2; UNCLASSIFIED DRUG; INTERCELLULAR ADHESION MOLECULE 1; NERVE GROWTH FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE EXACERBATION; DSM-IV; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; NONPARAMETRIC TEST; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MILD COGNITIVE IMPAIRMENT; NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STATISTICS, NONPARAMETRIC;

EID: 84897464653     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.01.019     Document Type: Article

References (73)

1. Adlard P.A., Cummings B.J. Alzheimer's disease-a sum greater than its parts?. Neurobiol Aging 2004, 25:725-733. [discussion 743-726].
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
3. Angelucci F., Spalletta G., di Iulio F., Ciaramella A., Salani F., Colantoni L., et al. Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res 2010, 7:15-20.
4. Ansar W., Ghosh S. C-reactive protein and the biology of disease. Immunol Res 2013, 56:131-142.
5. Arancibia S., Silhol M., Mouliere F., Meffre J., Hollinger I., Maurice T., et al. Protective effect of BDNF against β-amyloid induced neurotoxicity invitro and invivo in rats. Neurobiol Dis 2008, 31:316-326.
6. Barbosa I.G., Huguet R.B., Sousa L.P., Abreu M.N., Rocha N.P., Bauer M.E., et al. Circulating levels of GDNF in bipolar disorder. Neurosci Lett 2011, 502:103-106.
7. Barbosa I.G., Rocha N.P., Huguet R.B., Ferreira R.A., Salgado J.V., Carvalho L.A., et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. JAffect Disord 2012, 137:151-155.
8. Borba E.M. Associação dos níveis de BDNF (brain derived neurotrophic factor) no comprometimento cognitivo leve e na doença de Alzheimer, Faculdade de Medicina. Programa de Pós-Graduação em Medicina: Ciências Médicas 2012, Universidade Federal do Rio Grande do Sul, Brazil.
9. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000, 21:153-160.
10. Buchhave P., Zetterberg H., Blennow K., Minthon L., Janciauskiene S., Hansson O. Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 2010, 31:1877-1884.
11. Burbach G.J., Hellweg R., Haas C.A., Del Turco D., Deicke U., Abramowski D., et al. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. JNeurosci 2004, 24:2421-2430.
12. Caramelli P., Teixeira A.L., Buchpiguel C.A., Lee H.W., Livramento J.A., Fernandez L.L., et al. Diagnóstico de doença de Alzheimer no Brasil 2011, 11-20. Dementia e Neuropsychologia, Brazil.
13. Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995, 9:899-909.
14. Cook E.B., Stahl J.L., Graziano F.M., Barney N.P. Regulation of the receptor for TNFα, TNFR1, in human conjunctival epithelial cells. Invest Ophthalmol Vis Sci 2008, 49:3992-3998.
15. Derecki N.C., Cardani A.N., Yang C.H., Quinnies K.M., Crihfield A., Lynch K.R., et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. JExp Med 2010, 207:1067-1080.
16. Diez-Ruiz A., Tilz G.P., Zangerle R., Baier-Bitterlich G., Wachter H., Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995, 54:1-8.
17. Diniz B.S., Teixeira A.L., Ojopi E.B., Talib L.L., Mendonça V.A., Gattaz W.F., et al. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. JAlzheimers Dis 2010, 22:1305-1311.
18. Durany N., Michel T., Kurt J., Cruz-Sanchez F.F., Cervas-Navarro J., Riederer P. Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci 2000, 18:807-813.
19. Elfving B., Plougmann P.H., Müller H.K., Mathé A.A., Rosenberg R., Wegener G. Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 2010, 13:563-572.
20. Ewers M., Mielke M.M., Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol 2010, 45:75-79.
21. Ferrer I., Marin C., Rey M.J., Ribalta T., Goutan E., Blanco R., et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. JNeuropathol Exp Neurol 1999, 58:729-739.
22. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 1975, 12:189-198.
23. Forlenza O.V., Diniz B.S., Teixeira A.L., Ojopi E.B., Talib L.L., Mendonca V.A., et al. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry 2010, 11:774-780.
24. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007, 420:45-48.
25. Garzon D.J., Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. JNeurosci 2007, 27:2628-2635.
26. Giunta B., Fernandez F., Nikolic W.V., Obregon D., Rrapo E., Town T., et al. Inflammaging as a prodrome to Alzheimer's disease. JNeuroinflammation 2008, 5:51.
27. Hellweg R., Gericke C.A., Jendroska K., Hartung H.D., Cervos-Navarro J. NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int J Dev Neurosci 1998, 16:787-794.
28. Hock C., Heese K., Hulette C., Rosenberg C., Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000, 57:846-851.
29. Jofre-Monseny L., Loboda A., Wagner A.E., Huebbe P., Boesch-Saadatmandi C., Jozkowicz A., et al. Effects of apoE genotype on macrophage inflammation and heme oxygenase-1 expression. Biochem Biophys Res Commun 2007, 357:319-324.
30. Kao P.F., Banigan M.G., Vanderburg C.R., McKee A.C., Polgar P.R., Seshadri S., et al. Increased expression of TrkB and Capzb2 accompanies preserved cognitive status in early Alzheimer disease pathology. JNeuropathol Exp Neurol 2012, 71:654-664.
31. Karim S., Hopkins S., Purandare N., Crowther J., Morris J., Tyrrell P., et al. Peripheral inflammatory markers in amnestic mild cognitive impairment. Int J Geriatr Psychiatry 2013, 10.1002/gps.3988.
32. Katz S., Ford A.B., Moskowitz R.W., Jackson B.A., Jaffe M.W. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963, 185:914-919.
33. Kerschensteiner M., Gallmeier E., Behrens L., Leal V.V., Misgeld T., Klinkert W.E., et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor invitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. JExp Med 1999, 189:865-870.
34. Kerschensteiner M., Stadelmann C., Dechant G., Wekerle H., Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003, 53:292-304.
35. Kimura N., Negishi T., Ishii Y., Kyuwa S., Yoshikawa Y. Astroglial responses against Aβ initially occur in cerebral primary cortical cultures: species differences between rat and cynomolgus monkey. Neurosci Res 2004, 49:339-346.
36. Kimura N., Takahashi M., Tashiro T., Terao K. Amyloid β up-regulates brain-derived neurotrophic factor production from astrocytes: rescue from amyloid β-related neuritic degeneration. JNeurosci Res 2006, 84:782-789.
37. Klein A.B., Williamson R., Santini M.A., Clemmensen C., Ettrup A., Rios M., et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011, 14:347-353.
38. Lapchak P.A., Araujo D.M., Hefti F. Systemic interleukin-1β decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience 1993, 53:297-301.
39. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Wittorf A., Richartz E., et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. JNeural Transm 2006, 113:1217-1224.
40. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Maetzler W., Wittorf A., et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. JPsychiatr Res 2007, 41:387-394.
41. Leckie R.L., Weinstein A.M., Hodzic J.C., Erickson K.I. Potential moderators of physical activity on brain health. JAging Res 2012, 2012:948981.
42. Leduc V., Jasmin-Belanger S., Poirier J. APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med 2010, 16:469-477.
43. Lee J.G., Shin B.S., You Y.S., Kim J.E., Yoon S.W., Jeon D.W., et al. Decreased serum brain-derived neurotrophic factor levels in elderly Korean with dementia. Psychiatry Investig 2009, 6:299-305.
44. Leyhe T., Stransky E., Eschweiler G.W., Buchkremer G., Laske C. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2008, 258:124-128.
45. Linnarsson S., Bjorklund A., Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci 1997, 9:2581-2587.
46. Lista S., Garaci F.G., Ewers M., Teipel S., Zetterberg H., Blennow K., et al. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. Alzheimers Dement 2013, 10.1016/j.jalz.2013.04.506.
47. Lorigados Pedre L., Pavon Fuentes N., Alvarez Gonzalez L., McRae A., Serrano Sanchez T., Blanco Lescano L., et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res 2002, 952:122-127.
48. Marksteiner J., Kemmler G., Weiss E.M., Knaus G., Ullrich C., Mechtcheriakov S., et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2011, 32:539-540.
49. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
50. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
51. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989, 39:1159-1165.
52. Murase K., Furukawa Y., Iwane M., Hayashi K. Development of sensitive enzyme immunoassay for human nerve growth factor. Biochem Int 1991, 25:29-34.
53. Murer M.G., Boissiere F., Yan Q., Hunot S., Villares J., Faucheux B., et al. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience 1999, 88:1015-1032.
54. Nockher W.A., Renz H. Neurotrophins and asthma: novel insight into neuroimmune interaction. JAllergy Clin Immunol 2006, 117:67-71.
55. Papassotiropoulos A., Hock C., Nitsch R.M. Genetics of interleukin 6: implications for Alzheimer's disease. Neurobiol Aging 2001, 22:863-871.
56. de Paula J.J., Bertola L., Ávila R.T., Moreira L., Coutinho G., de Moraes E.N., et al. Clinical applicability and cutoff values for an unstructured neuropsychological assessment protocol for older adults with low formal education. PLoS One 2013, 8:e73167.
57. Petersen R.C. Mild cognitive impairment as a diagnostic entity. JIntern Med 2004, 256:183-194.
58. Pfeffer R.I., Kurosaki T.T., Harrah C.H., Chance J.M., Filos S. Measurement of functional activities in older adults in the community. JGerontol 1982, 37:323-329.
59. Phillips H.S., Hains J.M., Laramee G.R., Rosenthal A., Winslow J.W. Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science 1990, 250:290-294.
60. Poon W.W., Blurton-Jones M., Tu C.H., Feinberg L.M., Chabrier M.A., Harris J.W., et al. Beta-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiology of aging 2011, 32:821-833.
61. Rohe M., Synowitz M., Glass R., Paul S.M., Nykjaer A., Willnow T.E. Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. JNeurosci 2009, 29:15472-15478.
62. Rosen W.G., Terry R.D., Fuld P.A., Katzman R., Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980, 7:486-488.
63. Schaub R.T., Anders D., Golz G., Gohringer K., Hellweg R. Serum nerve growth factor concentration and its role in the preclinical stage of dementia. Am J Psychiatry 2002, 159:1227-1229.
64. Schulte-Herbrüggen O., Nassenstein C., Lommatzsch M., Quarcoo D., Renz H., Braun A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. JNeuroimmunol 2005, 160:204-209.
65. Serrano-Sanchez T., Robinson-Agramonte M.A., Lorigados-Pedre L., Diaz-Armesto I., Gonzalez-Fraguela M.E., Dorta-Contreras A.J. Rev Neurol 2001, 32:825-828.
66. Siegel G.J., Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 2000, 33:199-227.
67. Song F., Poljak A., Smythe G.A., Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev 2009, 61:69-80.
68. Straten G., Eschweiler G.W., Maetzler W., Laske C., Leyhe T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. JAlzheimers Dis 2009, 18:331-337.
69. Szekely C.A., Breitner J.C., Fitzpatrick A.L., Rea T.D., Psaty B.M., Kuller L.H., et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology 2008, 70:17-24.
70. Tasset I., Sanchez-Lopez F., Aguera E., Fernandez-Bolanos R., Sanchez F.M., Cruz-Guerrero A., et al. NGF and nitrosative stress in patients with Huntington's disease. J Neurol Sci 2012, 315:133-136.
71. Thornton E., Vink R., Blumbergs P.C., Van Den Heuvel C. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res 2006, 1094:38-46.
72. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011, 25:181-213.
73. Zhu Y., Nwabuisi-Heath E., Dumanis S.B., Tai L.M., Yu C., Rebeck G.W., et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia 2012, 60:559-569.